Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label, Randomized 2-arm Study Comparing the Clinical Efficacy and Safety of Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733 is registered in ClinicalTrials.gov with Ivy Brain Tumor Center as lead sponsor.

NCT NCT06388733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06388733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label, Randomized 2-arm Study Comparing the Clinical Efficacy and Safety of Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Lead sponsor
Ivy Brain Tumor Center
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 19, 2024
Completion date
March 31, 2028
Enrollment
450 (estimated)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

brain neoplasms, adult, malignant, brain tumor, gbm, glioblastoma